The clonal composition of myeloproliferative neoplasms (MPN) harboring both JAK2 V617 F and BCR::ABL1 [4, 5] and the outcomes of these patients are unclear and management remains challenging. This evidence concerns the gene BCR and myeloproliferative neoplasm.